checkAd

    YTEN - Yield10 Bioscience, Inc - Research License deal mit Monsanto - 500 Beiträge pro Seite

    eröffnet am 25.01.18 16:08:10 von
    neuester Beitrag 08.03.21 14:51:26 von
    Beiträge: 65
    ID: 1.272.535
    Aufrufe heute: 0
    Gesamt: 3.420
    Aktive User: 0

    ISIN: US98585K8624 · WKN: A2PYHH · Symbol: YTEN
    0,3700
     
    USD
    +10,25 %
    +0,0344 USD
    Letzter Kurs 01:00:00 NYSE

    Werte aus der Branche Chemie

    WertpapierKursPerf. %
    2,9600+48,00
    1,4900+34,23
    126,00+24,75
    43,26+13,87
    4,7800+13,81
    WertpapierKursPerf. %
    32,30-9,01
    810,05-9,49
    6,7557-9,92
    13,960-9,99
    5,3100-10,00

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 25.01.18 16:08:10
      Beitrag Nr. 1 ()
      Bin heute hier eingestiegen. Sieht interessant aus. Insbesondere der research license deal mit Monsanto.

      Im folgenden zwei News Releases aus jüngster Vergangenheit:

      Yield10 Bioscience Grants Research License to Monsanto to Evaluate Two Novel Yield Traits in Soybean
      GlobeNewswire•December 11, 2017


      WOBURN, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) announced today that it has granted a non-exclusive research license to Monsanto Company to evaluate its novel C3003 and C3004 yield traits in soybean. Under the license, Monsanto plans to research both traits within its soybean pipeline as a strategy to improve plant yields. Yield10 Bioscience is focused on "building better plants" by developing proprietary, breakthrough technologies that produce higher yields in major food and feed crops to enhance global food security using lower inputs of land, water and fertilizer.
      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…

      Yield10 Bioscience Announces Pricing of $12.6 Million Public Offering
      GlobeNewswire•December 19, 2017


      WOBURN, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) today announced the pricing of an underwritten public offering of units for gross proceeds of $12.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience.

      The offering is comprised of 3,828,000 Class A Units, priced at a public offering price of $2.25 per unit, with each unit consisting of one share of common stock, a five-year warrant to purchase one share of common stock at an exercise price of $2.25 per share, and a nine-month warrant to purchase 0.5 share of common stock at an exercise price of $2.25 per share, and 3,987 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of preferred stock, having a conversion price of $2.25, five-year warrants to purchase 445 shares of common stock with an exercise price of $2.25 per share, and nine-month warrants to purchase 223 shares of common stock with an exercise price of $2.25 per share. The conversion price of the preferred stock issued in the transaction and the exercise prices of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock), liquidation preference or other preferences over common stock, and, with certain exceptions, has no voting rights. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about December 21, 2017, subject to the satisfaction or waiver of customary closing conditions.
      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Avatar
      schrieb am 29.01.18 14:58:28
      Beitrag Nr. 2 ()
      Link presentation Yield10 Bioscience Third Quarter 2017 Earnings Call
      Nov 9, 2017
      http://ir.yield10bio.com/static-files/c2f232f8-fee1-4f74-941…

      Seite 13 value creation

      Seite 15 upcoming milestones
      Avatar
      schrieb am 29.01.18 18:03:56
      Beitrag Nr. 3 ()
      2.01+0.27 (+15.52%)
      As of 12:03PM EST.
      Avatar
      schrieb am 30.01.18 11:57:09
      Beitrag Nr. 4 ()
      Hallo zusammen, bin neu auf den Wert aufmerksam geworden. Der Kurs war ja schon Mal deutlich höher. Wie kommt der tiefe Fall zu Stande?
      Avatar
      schrieb am 22.02.18 20:10:29
      Beitrag Nr. 5 ()
      ich war auch kurz vor dem einstieg in Yiel10 Bioscience Inc., bis mir hier aufgefallen ist, dass die bude nur den namen (vorher Metabolix) und das geschäftsmodell geändert hat.

      sehr suspekt...

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 14.03.18 17:51:00
      Beitrag Nr. 6 ()
      Nice gain today :)
      Avatar
      schrieb am 18.04.18 20:41:59
      Beitrag Nr. 7 ()
      Habe heute hier wieder eine erste Position aufgebaut. Die Aktie ist sehr volatil und kann schnell auf $3 steigen. Cash reicht bis nächstes Jahr. Bis dahin werden meiner Ansicht nach genug News kommen, die für einen Kursanstieg sorgen werden. Time will tell...

      http://ir.yield10bio.com/news-releases/news-release-details/…
      "...the Company anticipates that its current cash resources will be sufficient to fund operations and meet its obligations for at least the next twelve months."
      Avatar
      schrieb am 19.04.18 17:23:26
      Beitrag Nr. 8 ()
      Company presentation:
      https://www.yield10bio.com/sites/default/files/YTEN_Investor…

      „Has significant, near-term milestones in major row crops
      • Data from field tests of C3003 in Camelina, canola and soybean expected in 2018
      • Progressing oil enhancing traits using CRISPR genome editing“
      Avatar
      schrieb am 20.04.18 11:11:26
      Beitrag Nr. 9 ()
      SeeThruEquity Issues Update on Yield10 Bioscience
      22 March 2018
      Price target of $8.50 for YTEN
      https://finance.yahoo.com/news/seethruequity-issues-yield10-…
      Avatar
      schrieb am 24.04.18 21:58:19
      Beitrag Nr. 10 ()
      Apr 24, 2018
      Yield10 Bioscience Announces Plans for its 2018 Field Test Program
      http://ir.yield10bio.com/news-releases/news-release-details/…
      Avatar
      schrieb am 26.04.18 09:55:03
      Beitrag Nr. 11 ()
      Nice end of day trading action. Keep on radar...
      Avatar
      schrieb am 26.04.18 14:47:20
      Beitrag Nr. 12 ()
      Apr 26, 2018
      Yield10 Addresses Application of Metabolic Engineering to Increase Crop Yield in Paper Published in Plant Science
      Chief Science Officer Kristi Snell also confirmed as a keynote speaker at upcoming plant meeting
      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Avatar
      schrieb am 08.05.18 14:42:30
      Beitrag Nr. 13 ()
      May 8, 2018
      Yield10 Researchers Publish Research in Plant Science Showing that Novel Transcription Factors Represent a Promising Approach for Increasing Crop Productivity

      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Avatar
      schrieb am 11.05.18 07:56:45
      Beitrag Nr. 14 ()
      Yield10 Bioscience's (YTEN) CEO Oli Peoples on Q1 2018 Results - Earnings Call Transcript
      May.10.18
      https://seekingalpha.com/article/4172681-yield10-biosciences…

      "We ended first quarter of 2018 with $11.6 million in cash, cash equivalents and short-term securities on the balance sheet."

      "We expect our cash on hand together with revenue expected under current government grants to support our operations to a number of technology proof points into mid-2019."

      "Monsanto is the world leader in developing biotech traits in soybean. So it’s great to have them working in C3003 with a unique capabilities and capacity. Our new business model for working with ag major, its also attracted the interest of other parties for both additional gene traits as well as other crops. We have some discussions ongoing and our goal is to work with additional ag companies to bring forward new yield traits."
      Avatar
      schrieb am 22.05.18 16:32:06
      Beitrag Nr. 15 ()
      Yield10 Bioscience Exercises Option with University of Missouri to Obtain Exclusive Worldwide License to Advanced Technologies for Oilseed Crops
      May 22, 2018
      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Avatar
      schrieb am 24.05.18 13:08:02
      Beitrag Nr. 16 ()
      SeeThruEquity Issues Update on Yield10 Bioscience, Inc.

      May 23, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Yield10 Bioscience, Inc. (NASDAQ: YTEN).

      https://www.accesswire.com/500588/SeeThruEquity-Issues-Updat…

      No change to price target at this time ($8.50)
      Our price target for YTEN is unchanged at this time. 1Q18 results set the stage for an important planting season, which should provide additional data for the company's portfolio of traits. We plan to re-evaluate the price target following results, a more expansive update of the Monsanto relationship, or more visibility into the company's other partnership discussions.
      Avatar
      schrieb am 21.06.18 15:40:25
      Beitrag Nr. 17 ()
      Yield10 Researchers Publish Research in Plant Cell Reports Describing the Development of its Camelina Platform as a Model Crop for Novel Yield Trait Discovery
      June 21, 2018
      https://globenewswire.com/news-release/2018/06/21/1527841/0/…
      Avatar
      schrieb am 12.07.18 21:14:01
      Beitrag Nr. 18 ()
      July 12, 2018
      Maxim Group analyst began coverage with a Buy rating on Yield10 Bioscience (YTEN) today and set a price target of $7.
      https://hillaryhq.com/2018/07/12/maxim-group-covers-yield10-…
      Avatar
      schrieb am 08.08.18 14:41:15
      Beitrag Nr. 19 ()
      Aug 8, 2018
      Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer

      WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced it has signed a non-exclusive research license agreement jointly with the Broad Institute of MIT and Harvard and Pioneer, part of Corteva AgriscienceTM Agriculture Division of DowDuPont (NYSE - DWDP), for the use of CRISPR-Cas9 genome-editing technology for crops. The joint license covers intellectual property consisting of approximately 48 patents and patent applications on CRISPR-Cas9 technology controlled by the Broad Institute and Pioneer. Under the agreement, Yield10 has the option to renew the license on an annual basis and the right to convert the research license to a commercial license in the future, subject to customary conditions as specified in the agreement.

      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Avatar
      schrieb am 06.09.18 11:26:23
      Beitrag Nr. 20 ()
      Yield10 Bioscience Reports Promising Seed Yield Results for Novel Yield Trait C3004 in Growth Chamber Studies in Camelina
      --Fast-Tracking Deployment of C3004 Trait into Canola and Soybean

      WOBURN, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced promising results for its novel yield trait C3004 in growth chamber studies conducted using its Camelina platform. Camelina plant lines containing C3004 grew vigorously, and the best lines produced increases in seed yield in a range of 26% to 65% as compared to control plants. Yield10 plans to conduct field tests of the C3004 trait in Camelina as part of its 2019 Field Test program in Canada. In addition, Yield10 is fast tracking deployment of the C3004 trait into canola and soybean to determine if the trait produces similar effects on plant vigor and seed yield in major oilseed crops.

      “Our early research results with C3004 in Camelina including plant growth and vigor, branching and seed yield, though preliminary, are very encouraging,” said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. “These initial seed yield data for C3004 suggest we can harness the metabolic machinery of plants to drive robust increases in seed yield in Camelina. The next step is to determine if the effects of C3004 on plant vigor and seed yield can be successfully achieved in Camelina under field conditions and translated into canola, soybean and other commercial crops.”
      https://globenewswire.com/news-release/2018/09/05/1565554/0/…" target="_blank" rel="nofollow ugc noopener">
      https://globenewswire.com/news-release/2018/09/05/1565554/0/…
      Avatar
      schrieb am 13.09.18 22:38:54
      Beitrag Nr. 21 ()
      in Meinen Augen ist noch zu früh.
      Avatar
      schrieb am 21.09.18 15:11:05
      Beitrag Nr. 22 ()
      Sep 21, 2018
      Yield10 Bioscience Grants Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum

      WOBURN, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today announced that it has granted a non-exclusive research license to Forage Genetics International, LLC, a subsidiary of Land O’Lakes, Inc., to evaluate five novel yield traits in forage sorghum. Under the license, Forage Genetics plans to conduct research with the novel traits within its sorghum development program as a strategy to improve biomass yields.

      http://ir.yield10bio.com/news-releases/news-release-details/…


      Wikipedia:
      Land O'Lakes ist eine Agrargenossenschaft US-amerikanischer Milchbauern mit Sitz in Minneapolis-St. Paul. Sie hat rund 3.600 direkte Mitglieder und rund 850 angeschlossene Genossenschaften mit über 300.000 Genossen (Stand 2013).[1]

      Neben dem Geschäft mit Milchprodukten gehören auch der Futtermittelhersteller Purina Mills, der 2001 von Vorbesitzer Ralston Purina übernommen wurde,[2] sowie der Saatgut- und Pestizidhändler WinField Solutions zu Land O'Lakes
      Avatar
      schrieb am 02.10.18 17:23:59
      Beitrag Nr. 23 ()
      Oct 2, 2018
      Yield10 Bioscience Obtains Nonregulated Status for its Novel CRISPR-Cas9 Triple Gene Edited Camelina Plant Lines to Boost Seed Oil Content

      --USDA-APHIS Response Marks Clearance of Yield10’s First Triple Genome-edited Plant Lines

      --Favorable Response Accelerates Path to U.S. Field Trials in 2019
      http://ir.yield10bio.com/news-releases/news-release-details/…" target="_blank" rel="nofollow ugc noopener">
      http://ir.yield10bio.com/news-releases/news-release-details/…
      2 Antworten
      Avatar
      schrieb am 06.11.18 22:55:30
      Beitrag Nr. 24 ()
      Antwort auf Beitrag Nr.: 58.854.537 von iknowtheway am 02.10.18 17:23:59Wenn Du auf AgriYieldBoosterEntwicklerFirmen stehst:

      RKDA(.Lo) ist auch interessant.
      Aber die Zeit ist NOCH nicht gekommen.
      1 Antwort
      Avatar
      schrieb am 08.11.18 12:52:44
      Beitrag Nr. 25 ()
      Antwort auf Beitrag Nr.: 59.153.250 von Popeye82 am 06.11.18 22:55:30Danke, interessanter Wert, werde ich mir mal genauer anschauen.

      Bei YTEN hoffe ich auf baldige news. Die Field Test Ergebnisse dürften hoffentlich gut ausfallen.
      Avatar
      schrieb am 08.11.18 19:08:22
      Beitrag Nr. 26 ()
      The Meteoric Rise of Genomics
      November 8, 2018
      https://www.agribusinessglobal.com/seeds-traits/the-meteoric…
      2 Antworten
      Avatar
      schrieb am 08.11.18 21:11:31
      Beitrag Nr. 27 ()
      Antwort auf Beitrag Nr.: 59.171.406 von iknowtheway am 08.11.18 19:08:22IknowTheWay

      Was Mich mal interessieren würde.

      Wie siehs Du persönlich denn Dieses "GMO" DIng?
      Also aus der Beobachtung raus kann ich auf Jeden Fall sagen dass man "genetically modified organsims" in Den United States wohl ziemlich positiv, offensiv, aufgeschlossen gegenüber steht, in Europa/Deutschland eher sehr, sehr skeptisch. Das GANZE Gegenteil.

      Also ich habe Eine Eigene Meinung, Dazu, will aber überhaupt nicht sagen Was jetzt "richtig" ist.
      Aber ziemlich offensichtlich ist ja: Wenn weltweit gesehen demographisch nicht "Irgendwelche ganz Einschneidenden Sachen passieren", dass Wir in Einigen Sachen auf sehr, sehr, sehr Grosse Probleme zusteuern dürften. Wahrscheinlich richtig UGLY werden.

      Also ich will Jetzt nicht sagen: "So ist es, und Anders nicht". Aber mal (D)Eine Sicht hören. In Bezug auf "GMO"s.
      1 Antwort
      Avatar
      schrieb am 08.11.18 22:04:32
      Beitrag Nr. 28 ()
      Antwort auf Beitrag Nr.: 59.172.549 von Popeye82 am 08.11.18 21:11:31Grundsätzlich habe ich mit der Technologie keine Probleme. Wenn ich das richtig verstehe, ist bei dem derzeitigen Bevölkerungswachstum eine Versorgung der Weltbevölkerung nur mit Gentechnik möglich, wenn überhaupt.

      Rauchen ist so mit das ungesündeste, und das gibt man sich ja freiwillig...
      Avatar
      schrieb am 09.11.18 11:55:38
      Beitrag Nr. 29 ()
      Genome Editing: Bioökonomierat fordert neues EU-Gentechnikrecht

      Der Bioökonomierat legt eine differenzierte Bewertung der CRISPR-Technologie vor und appelliert an die Politik, das Gentechnikrecht zu modernisieren. Andernfalls bleibe Deutschland bei dieser „biologischen Revolution“ außen vor und werde auch die notwendige internationale Regulierung nicht mitgestalten.
      09.10.2018

      von Alfons Deter

      https://www.topagrar.com/acker/news/genome-editing-biooekono…
      Avatar
      schrieb am 28.11.18 15:09:55
      Beitrag Nr. 30 ()
      To fulfill biofuels’ promise, scientists boost plant oils with gene editing
      November 25, 2018
      https://cen.acs.org/energy/biofuels/fulfill-biofuelspromise-…

      ...
      To Peoples, the future looks promising. A 20% increase in the yield of conventional oil crops like canola and soybean could boost the economic value of these crops by $10 billion, he says. If the current techniques work well in camelina, the company will attempt similar gene edits in canola and soybeans.

      Although Yield10’s primary goal is to sell its camelina oil for human health products and as an ingredient for agricultural animal feed rather than as a feedstock for biofuels, Peoples says the gene-editing discovery made by Yield10 could be beneficial for that type of application too.

      Yield10 won’t disclose the exact edits its scientists made to improve camelina’s oil production, citing proprietary information. But presentation slides shared online on Nov. 4 for investors indicate that edits to genes that the firm calls C3008a, C3008b, and C3009 work to increase oil production by simultaneously increasing fatty acid biosynthesis and blocking the metabolism of the synthesized lipid.

      At the same time, Yield10’s Canadian subsidiary, Metabolix Oilseeds, is working to edit a gene the company has called C3007 in camelina and canola. Gene C3007 encodes a protein that negatively regulates a key enzyme in fatty acid biosynthesis, acetyl-CoA carboxylase. By decreasing the activity of this negative regulator, the firm aims to boost the enzyme’s activity and make more plant oil.
      ...
      Avatar
      schrieb am 03.12.18 19:25:27
      Beitrag Nr. 31 ()
      Interessanter Artikel über YTEN und CRISPR
      November 30, 2018
      http://www.wbur.org/commonhealth/2018/11/30/gene-edited-food…
      Avatar
      schrieb am 04.12.18 09:05:01
      Beitrag Nr. 32 ()
      Increasing Crop Yield Through Smart Approaches In Trait Discovery
      December 3, 2018
      https://sciencetrends.com/increasing-crop-yield-through-smar…

      In Yield10’s research, the use of these models from the perspective of the company’s trait discovery and development program are detailed extensively, and one day may make significant impacts on the cost and timeline for developing new yield traits for major row crops – all of which could help in the challenge of addressing global food security challenges.
      Avatar
      schrieb am 11.12.18 22:28:33
      Beitrag Nr. 33 ()
      Yield10 twitter account:

      Yield10 Bioscience @Yield10Bio
      We are thrilled that the segment in which we participated with @commonhealth / @WBUR on the use of CRISPR and gene/genome editing technologies to impact crop yield, was featured on @HereAndNow!

      https://www.wbur.org/hereandnow/2018/12/10/gene-edited-food-…
      Avatar
      schrieb am 13.12.18 15:23:51
      Beitrag Nr. 34 ()
      Dec 13, 2018
      Yield10 Bioscience Names Sherri M. Brown, Ph.D., Former Monsanto Executive, as Special Commercial and Technical Advisor

      WOBURN, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today named Sherri M. Brown, Ph.D., as a special commercial and technical advisor to the Company, effective immediately. Dr. Brown is currently managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in a number of leadership positions involving the development and global commercialization of new biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years.

      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      1 Antwort
      Avatar
      schrieb am 13.12.18 17:09:23
      Beitrag Nr. 35 ()
      Antwort auf Beitrag Nr.: 59.432.211 von iknowtheway am 13.12.18 15:23:51Blonder,

      Für Informationen,
      vielleicht ein paar Zusätzliche,
      kannst Du auch ---->Hier<---- mal reinsehen:
      www.seethruequity.com/wp-content/uploads/2017/08/YTEN-INITIA…
      www.seethruequity.com/research/
      Avatar
      schrieb am 03.01.19 03:33:56
      Beitrag Nr. 36 ()
      Avatar
      schrieb am 26.01.19 12:42:51
      Beitrag Nr. 37 ()
      Yield10 Bioscience (YTEN) Now Covered by National Securities
      Jan 25th, 2019
      https://www.modernreaders.com/news/2019/01/25/yield10-biosci…

      Yield10 Bioscience logoInvestment analysts at National Securities initiated coverage on shares of Yield10 Bioscience (NASDAQ:YTEN) in a report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating and a $5.00 price target on the specialty chemicals company’s stock.

      Commercial Relationships In Early Stages. Since late 2017, two research license agreements have been reached with Monsanto and Forage Genetics International, major players in the soybean and sorghum markets, respectively. While these are research agreements for now, we believe these announcements validate Yield10’s technology and represent the kind of relationships that could generate commercial revenue.

      High Ceiling Value. Between the value of the IP portfolio in the near term, and the potential value provided by commercial revenue streams, we believe shares of Yield10 could prove to be materially undervalued at current levels. Should commercialization agreements materialize, we believe our twelve month price target could prove to be conservative.”
      Avatar
      schrieb am 26.01.19 19:21:23
      Beitrag Nr. 38 ()
      Wer zu Diesem "CRISPR" dümmer werden will, UNBEDINGT lesen!
      www.abc.net.au/news/science/2016-04-07/crispr-gene-editing-t…
      Avatar
      schrieb am 12.02.19 22:49:20
      Beitrag Nr. 39 ()
      YTEN Investor Presentation February 2019
      http://ir.yield10bio.com/static-files/a105a7f1-3979-4775-8f6…
      1 Antwort
      Avatar
      schrieb am 26.02.19 17:34:44
      Beitrag Nr. 40 ()
      GM-No? Yield10 Bioscience is Developing Gene-Edited Corn for Increased Yields
      By
      Catherine Lamb - February 25, 2019
      https://thespoon.tech/gm-no-yield10-bioscience-is-developing…
      Avatar
      schrieb am 14.03.19 19:40:29
      Beitrag Nr. 41 ()
      :) Mal sehen wie es weiter geht...
      Avatar
      schrieb am 14.03.19 21:53:45
      Beitrag Nr. 42 ()
      Antwort auf Beitrag Nr.: 59.858.047 von iknowtheway am 12.02.19 22:49:20YOU are not authorized to access this page.
      Avatar
      schrieb am 15.03.19 18:39:44
      Beitrag Nr. 43 ()
      Manchmal braucht man eben etwas Glück :D
      Mein Verkaufsorder von 1,70 gestern hatte gezogen. Bin weiterhin von Yield10 überzeugt. Werde in den kommenden Woche wieder eine Position aufbauen.

      Mar 15, 2019
      Yield10 Bioscience Announces Pricing of $2.9 Million Registered Direct Offering
      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Avatar
      schrieb am 12.08.19 18:51:35
      Beitrag Nr. 44 ()
      Aug 12, 2019
      Yield10 Bioscience Announces Notice of Allowance for U.S. Patent Covering Crop Yield Trait C4001

      WOBURN, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office allowing its patent application covering the use of C4001 to improve productivity in crops.
      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Yield10 Bioscience | 0,960 $
      Avatar
      schrieb am 09.10.19 18:49:33
      Beitrag Nr. 45 ()
      Habe hier wieder in den vergangenen Wochen eine Position aufgebaut. Hoffe auf gute news in den kommenden Monaten.

      Aug. 12, 2019
      Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2019 Results - Earnings Call Transcript
      https://seekingalpha.com/article/4285013-yield10-bioscience-…

      “CBD is a good example of a product targets for Yield10's traits and capabilities that considerable value for third-party with deep knowledge of the medical CBD business. Yet we're seeing a funded R&D program and upfront payments research funding and license revenues, as appropriate. These product targets provide opportunities for Yield10 to develop businesses that generate product revenue and/or partnerships of downstream revenue. We will keep you posted as it continues to make progress and finalize the business cases.

      “And we're also actively engaged in discussions with third parties interested in deploying our traits in a variety of other commercially important crops. We plan to keep you updated on the progress we're making all of these areas in the second half 2019.
      Yield10 Bioscience | 0,630 $
      Avatar
      schrieb am 10.10.19 13:50:50
      Beitrag Nr. 46 ()
      Interessante Einschätzung von National Research.

      Yield10 Bioscience’s (NASDAQ:YTEN) Buy Rating Reiterated at National Securities
      Thursday, September 12th, 2019
      https://rivertonroll.com/news/2019/09/12/yield10-bioscience-…

      The firm currently has a $5.00 price target company’s stock.

      - Additional Genes Now Under Consideration. The research license with Bayer (STU: BAY – NR – €66.48) has been amended to include an expanded scope for the C3004 trait. Under the original agreement signed in late 2017, BAY considered the C3003 and C3004 traits for evaluation in soybean, with the genes under consideration targeted to controlling carbon flow. With YTEN’s additional discoveries in the C3004 trait from 2018 trials in camelina, the research license was expanded to include a broader scope of genes.
      - A Validation Of Technology? We expect that since the December 2017 license was signed that BAY has studied the C3003 and C3004 traits within its soybean varieties in greenhouse settings, and moved to field trials in Spring 2019. We believe that BAY could easily terminate the agreement if it saw no commercial potential, and we believe the expanded scope represents a validation of YTEN technology.
      - No Better Commercial Partner. Following BAY’s acquisition of Monsanto, it controls roughly one third of global soybean sales, and its overall market share is significantly greater when considering seed distributed by peers which include BAY licensed traits. We believe of the major commercial crops that there is no better partner for YTEN than BAY and its soybean market.
      - Additional Agreements Needed, May Come With Funded R&D. We anticipate that YTEN is in active discussions with other commercial partners and believe future research agreements may come with a funded R&D component.,” National Securities’ analyst wrote.
      Yield10 Bioscience | 0,625 €
      Avatar
      schrieb am 12.10.19 16:41:57
      Beitrag Nr. 47 ()
      Neben der Zusammenarbeit mit Bayer/Monsanto hat YTEN auch eine "Research License to Forage Genetics to Evaluate Novel Yield Traits in Sorghum" vergeben. Forage Genetics ist eine Tochtergesellschaft von Land O’Lakes, Inc. Laut Wikipedia beläuft sich der Jahresumsatz von Land O’Lakes auf 15 Milliarden US-Dollar. Hoffentlich kommen noch mehr solcher Ag industry collaborations.

      Link: http://ir.yield10bio.com/node/14091/pdf
      Yield10 Bioscience | 0,635 $
      Avatar
      schrieb am 18.10.19 23:46:06
      Beitrag Nr. 48 ()
      Die Aktie könnte mal wieder gute news gebrauchen. 2019 field test results werden für Q4 erwartet.
      Yield10 Bioscience | 0,649 $
      Avatar
      schrieb am 23.10.19 18:54:05
      Beitrag Nr. 49 ()
      Oct 23, 2019
      Yield10 Bioscience Signs Research Agreement with J. R. Simplot to Evaluate New Traits to Produce High Yielding, Sustainable Potato Crop
      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
      Yield10 Bioscience | 0,621 $
      Avatar
      schrieb am 24.10.19 15:20:03
      Beitrag Nr. 50 ()
      Die Research License mit J. R. Simplot Company ist ein weiterer großer Gewinn für YTEN. Die J. R. Simplot Company ist ein milliardenschweres Unternehmen und ein großer Anbieter von Kartoffeln.

      https://en.wikipedia.org/wiki/Simplot

      Unter anderem ist die J. R. Simplot Company ein großer Lieferant von Pommes für McDonald's.
      Yield10 Bioscience | 0,565 €
      Avatar
      schrieb am 07.11.19 19:45:37
      Beitrag Nr. 51 ()
      Habe heute nochmal Aktien nachgekauft. Mal sehen...
      Yield10 Bioscience | 0,345 $
      Avatar
      schrieb am 13.11.19 16:10:23
      Beitrag Nr. 52 ()
      Nov 12, 2019
      Yield10 Bioscience Announces Third Quarter 2019 Financial Results

      WOBURN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today reported financial results for the three and nine months ended September 30, 2019.

      https://yield10bioscienceinc.gcs-web.com/news-releases/news-…

      Recent Progress Achieving 2019 Milestones

      Expanded the research agreement with Bayer for evaluation of a new discovery related to the C3004 yield trait gene in soybean. Under the amended research license, Bayer will have access to new developments from Yield10’s C3004 program based on advanced technology related to the C3004 trait and its potential to increase seed yield.

      Signed a research agreement with J. R. Simplot Company, to evaluate novel new traits to produce high yielding, sustainable potato crop. Under the agreement with Yield10, Simplot plans to conduct research with three yield traits (C3003, C3004, C4001) within its research and development program as a strategy to improve crop performance and sustainability. In addition to the three-year, non-exclusive research agreement, Simplot was granted an option to negotiate an exclusive commercial license agreement.

      Presented research showcasing the Camelina Platform for producing PHB biomaterials to improve water quality. At the 3rd International Conference on Plant Synthetic Biology held in October, Yield10’s CSO Dr. Kristi Snell highlighted the scientific breakthrough achieved by Yield10 researchers demonstrating the ability to produce PHB biomaterials at the level of 10% of the mature seed weight in seeds of Camelina. PHB-producing Camelina can improve the sustainability of food production as a cover crop, by mitigating nutrient runoff at its source in the field, while also producing a PHB product for use as a denitrifying agent for water treatment that provides revenue to the farmer.
      Yield10 Bioscience | 0,323 $
      Avatar
      schrieb am 06.05.20 22:45:36
      Beitrag Nr. 53 ()
      Habe heute am Ende des Handelstages wieder eine erste Position gekauft. Vermutlich werde ich meine Position weiter ausbauen in Abhängigkeit von der weiteren Kursentwicklung. Die aktuelle Marktkapitalisierung entspricht dem aktuellen Cash. Das Cash reicht bis ins zweite Quartal 2021. Dies sollte YTEN genügend Zeit geben, um einige Meilensteine zu erreichen, die den Aktienkurs ankurbeln können.
      Yield10 Bioscience | 5,050 €
      Avatar
      schrieb am 15.05.20 09:24:44
      Beitrag Nr. 54 ()
      Yield10 Bioscience Secures Regulatory Permits for U.S. and Canadian Sites and Announces Plans for 2020 Field Test Program in Camelina and Canola

      May 14, 2020
      http://ir.yield10bio.com/node/15136/pdf
      Yield10 Bioscience | 6,450 €
      Avatar
      schrieb am 15.05.20 17:15:49
      Beitrag Nr. 55 ()
      Bin heute raus mit 10% plus. Warte dann auf niedrigere Einstiegskurse...
      Yield10 Bioscience | 5,280 $
      Avatar
      schrieb am 23.08.20 11:48:13
      Beitrag Nr. 56 ()
      Hier dürfte es bald gute Einstiegskurse geben. Gute Technologie, das Unternehmen ist immer für einen schnellen Doppler mit guten News zu haben...

      Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement
      August 23, 2020
      WOBURN, Mass., Aug. 22, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, todayannounced the pricing of its underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. The grossproceeds from the public offering will be approximately $3.5 million, before deducting underwriting discounts and commissions and estimated offeringexpenses. In addition, Yield10 also announced that investors affiliated with existing investor Jack W. Schuler, have agreed to purchase 396,450 sharesof Yield10’s common stock pursuant to a securities purchase agreement with Yield10 at the same price per share as in the public offering, in aseparate private placement transaction that is expected to close concurrently with the public offering. The gross proceeds from the private placementwill be approximately $1.7 million. All shares in the public offering and private placement are to be sold by Yield10.

      http://ir.yield10bio.com/node/15331/pdf
      Yield10 Bioscience | 4,340 €
      Avatar
      schrieb am 10.09.20 18:46:22
      Beitrag Nr. 57 ()
      Yield10 Bioscience Announces Participation at The H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

      Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will provide an overview of the Company's business during the live presentation on Monday, September 14, 2020 at 11:00 am Eastern Time and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

      https://finance.yahoo.com/news/yield10-bioscience-announces-…
      Yield10 Bioscience | 6,970 $
      2 Antworten
      Avatar
      schrieb am 10.09.20 21:40:44
      Beitrag Nr. 58 ()
      Antwort auf Beitrag Nr.: 65.045.967 von Malecon am 10.09.20 18:46:22Hier der mögliche Grund für den heutigen Anstieg...

      With a current rating of Buy, HC Wainwright & Co. initiated coverage on Yield10 Bioscience Inc (NASDAQ: YTEN). The price target seems to have been set at $25.00 for Yield10 Bioscience. For the second quarter, Yield10 Bioscience had an EPS of $0.75, compared to year-ago quarter EPS of $0.15. The current stock performance of Yield10 Bioscience shows a 52-week-high of $14.69 and a 52-week-low of $0.11. Moreover, at the end of the last trading period, the closing price was at $4.35.

      https://finance.yahoo.com/news/benzingas-top-upgrades-downgr…
      Yield10 Bioscience | 6,280 $
      1 Antwort
      Avatar
      schrieb am 10.09.20 21:51:34
      Beitrag Nr. 59 ()
      Antwort auf Beitrag Nr.: 65.047.929 von iknowtheway am 10.09.20 21:40:44
      Zitat von iknowtheway: The price target seems to have been set at $25.00 for Yield10 Bioscience.

      Kursziel $ 25 ? :eek: Wow. Mama mia!
      Yield10 Bioscience | 6,440 $
      Avatar
      schrieb am 15.01.21 21:41:36
      Beitrag Nr. 60 ()
      Hohes Volumen heute...
      Yield10 Bioscience | 11,86 $
      1 Antwort
      Avatar
      schrieb am 17.01.21 16:32:45
      Beitrag Nr. 61 ()
      Antwort auf Beitrag Nr.: 66.465.092 von iknowtheway am 15.01.21 21:41:36Was ist da los? Irgendein Durchbruch? Bin ab Montag auch mal dabei. Riesiges Potential, wenn sich da erstmal ein Hype lostritt.

      https://www.genengnews.com/commentary/point-of-view/sowing-t…

      Vom 8.1.21

      Achtet auf diese Aussage!!!!!!!!!!!!

      "Now, I know we still have lot of work ahead of us to develop commercial PHA Camelina varieties, but it’s only a matter of time before we can farm Camelina to produce natural PHA resin alternatives for plastic packaging materials and straws, knives, forks, and spoons. These can then be combined with food waste for biogas energy recovery, creating a closed-loop zero-waste system."

      Stellt euch vor, der Firma gelingt dieser Durchbruch. Das würde die Plastikerzeugung für Verpackungen revolutionieren. Das könnte den Kurs 100fach ansteigen lassen! Dagegen sind die 45 MCap die jetzt erreicht wurden geradezu ein Witz. Die Branche ist generell noch sehr unter dem Radar.
      Yield10 Bioscience | 13,71 $
      Avatar
      schrieb am 17.01.21 16:38:30
      Beitrag Nr. 62 ()



      So geht ein Ausbruch:





      🎵
      Yield10 Bioscience | 13,71 $
      2 Antworten
      Avatar
      schrieb am 17.01.21 21:54:32
      Beitrag Nr. 63 ()
      Antwort auf Beitrag Nr.: 66.478.010 von Malecon am 17.01.21 16:38:30Wenn sie nochmal auf 8-10 runterkommt, halt ich gegen ;)
      Yield10 Bioscience | 13,71 $
      Avatar
      schrieb am 17.01.21 22:00:48
      Beitrag Nr. 64 ()
      Antwort auf Beitrag Nr.: 66.478.010 von Malecon am 17.01.21 16:38:30Lasst euch von dem Aktienpreis nicht täuschen, die Marketcap liegt nun höher als 2017
      Yield10 Bioscience | 13,71 $
      Avatar
      schrieb am 08.03.21 14:51:26
      Beitrag Nr. 65 ()



      Die Analysten halten die Aktie für unterbewertet:


      Yield10 Bioscience – Consensus Indicates Potential 90.2% Upside

      Yield10 Bioscience with ticker code (YTEN) now have 4 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 30 and 24 calculating the average target price we see 26.5. With the stocks previous close at 13.93 this would imply there is a potential upside of 90.2%.

      https://www.directorstalkinterviews.com/yield10-bioscience--…


      Chart #1:




      Chart #2:




      💡
      Yield10 Bioscience | 10,70 €


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      YTEN - Yield10 Bioscience, Inc - Research License deal mit Monsanto